Newly expanded facilities include two segregated laboratories in which multi-stage synthesis to cGMP standards is carried out.

The GMP suite, which has an independent air handling system, with HEPA filters on input and output, has been designed to enable the safe handling of cytotoxics. We operate in glass-ware up to 20 litres in scale, typically enabling production in batches of up to multi kilo quantities.

We have been MHRA inspected and are in general compliance with the principles and guidelines of good manufacturing practice as laid down in Annex 18 of the EU Guide.

The activities approved were for the manufacture, testing and release of small scale active pharmaceutical ingredients for use in clinical trials.